<DOC>
<DOCNO>EP-0652968</DOCNO> 
<TEXT>
<INVENTION-TITLE>
DEFECTIVE ADENOVIRUSES
</INVENTION-TITLE>
<CLASSIFICATIONS>C12N15861	C07K14075	C12N15861	C12N704	C12N1531	C12N1509	C07K14435	C07K14395	C07K1447	C12N1509	C12N1512	C07K14005	A61K3512	C12N1531	A61K3512	A61K4800	C12N510	A61K4800	C07K1457	C12N1534	C12N510	A61K3800	C12N704	A61K3800	C12N701	C12N1512	C07K1437	C12N701	C12N1534	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C12N	C07K	C12N	C12N	C12N	C12N	C07K	C07K	C07K	C12N	C12N	C07K	A61K	C12N	A61K	A61K	C12N	A61K	C07K	C12N	C12N	A61K	C12N	A61K	C12N	C12N	C07K	C12N	C12N	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C12N15	C07K14	C12N15	C12N7	C12N15	C12N15	C07K14	C07K14	C07K14	C12N15	C12N15	C07K14	A61K35	C12N15	A61K35	A61K48	C12N5	A61K48	C07K14	C12N15	C12N5	A61K38	C12N7	A61K38	C12N7	C12N15	C07K14	C12N7	C12N15	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Novel defective adenoviruses for the transfer and expression of an exogenous nucleotide sequence in a host cell or organism. The invention also relates to novel complementation lines and to the process for the preparation of these novel defective adenoviruses and their use in therapy and to a pharmaceutical composition containing same.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
TRANSGENE SA
</APPLICANT-NAME>
<APPLICANT-NAME>
TRANSGENE S.A.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
IMLER JEAN-LUC
</INVENTOR-NAME>
<INVENTOR-NAME>
METHALI MAJID
</INVENTOR-NAME>
<INVENTOR-NAME>
PAVIRANI ANDREA
</INVENTOR-NAME>
<INVENTOR-NAME>
IMLER, JEAN-LUC
</INVENTOR-NAME>
<INVENTOR-NAME>
METHALI, MAJID
</INVENTOR-NAME>
<INVENTOR-NAME>
PAVIRANI, ANDREA
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
An adenoviral vector which is defective for replication, capable of being
encapsidated in a complementation cell and which is derived from the genome

of an adenovirus comprising, from 5' to 3', a 5' ITR, an encapsidation region,
an E1A region, an E1B region, an E2 region, an E3 region, an E4 region and a

3' ITR, by deletion

(i) in the E1A region and in the E2 region; or
(ii) in the E1A region, in the E2 region and in the E1B region; or
(iii) in the E1A region, in the E2 region and in the E3 region; or
(iv) in the E1A region, in the E2 region, in the E1B region and in the E3
region; or
(v) in the E1A region, in the E2 region and in the E4 region; or
(vi) in the E1A region, in the E2 region, in E1B region and in the E4 region;
or
(vii) in the E1A region, in the E2 region, in the E3 region and in the E4
region; or
(viii) in the E1A region, in the E2 region, in the E1B region, in the E3 region
and in the E4 region,

wherein said deletions prevent the production of at least one expression
product encoded by said regions, provided that the vector is not an adenoviral

vector only comprising the 5' and 3' ITRs and the region which is placed at the

5' extremity of the genome just behind the 5' ITR, enclosing the encapsidation
sequence and the E1A enhancer sequence.
The adenoviral vector according to claim 1(iii), (iv), (vii) or (viii) which is
derived from the genome of an adenovirus by partial deletion of the E3 region

of said genome by maintaining the portion of said E3 region which codes for
the gp19kDa protein.
The adenoviral vector according to claim 2, in which the portion of the E3
region which codes for the gp19kDa protein is placed under the control of

elements suitable for expression of said protein in the host cell. 
The adenoviral vector according to one of claims 1 to 3, which is derived from
the genome of an adenovirus selected from canine, avian and human

adenoviruses.
The adenoviral vector according to claim 4, which is derived from the genome
of a type-5 human adenovirus.
The adenoviral vector according to claim 5, in which the deletion of the portion
of the E3 region extends from nucleotide 27871 to nucleotide 30748.
The adenoviral vector according to one of the claims 1 to 6, which is derived
from the genome of an adenovirus by deletion of at least 18% of the genome

of said virus.
The adenoviral vector according to claim 7, which is derived from the genome
of an adenovirus by deletion of at least 22% of the genome of said virus.
The adenoviral vector according to claim 8, which is derived from the genome
of an adenovirus by deletion of at least 40% of the genome of said virus.
The adenoviral vector according to claim 9, which is derived from the genome
of an adenovirus by deletion of at least 95% of the genome of said virus.
An adenoviral vector which is derived from the genome of a type-5 human
adenovirus by deletion of the portion of the viral genome extending from

nucleotides 459 to 35832.
The adenoviral vector according to one of claims 1 to 11, which furthermore
comprises an exogenous nucleotide sequence.
The adenoviral vector according to claim 12, which furthermore comprises a
gene of interest placed under the control of elements necessary for its

expression. 
The adenoviral vector according to one of claims 12 to 13, which furthermore
comprises a gene coding for a non-adenoviral transcription trans-activator

protein; said gene being placed under the control of elements necessary for
the expression of said protein in a host cell.
The adenoviral vector according to claim 14, comprising the gene coding for
the transcription trans-activator protein Gal4 of 
Saccharomyces cerevisiae.
An adenovirus particle comprising an adenoviral vector according to one of
claims 1 to 15.
A eukaryotic host cell comprising an adenoviral vector according to one of
claims 1 to 15 or an adenovirus particle according to claim 16.
A process for the preparation of an adenovirus particle according to claim 16,
in which:


(i) an adenoviral vector according to one of claims 1 to 15 is introduced
into a complementation line capable of complementing 
in trans
 said
adenoviral vector so as to obtain a transfected complementation line;
(ii) the said transfected complementation line is cultured under suitable
conditions for permitting the production of said adenovirus particle; and
(iii) the said adenovirus particle is recovered in the cell culture.
The process according to claim 18, wherein said complementation line
contains a complementation element comprising, in particular, a portion of the

E1 region of the genome of an adenovirus with the exception of the 5' ITR; the
said complementation element being capable of complementing 
in trans
 a
defective adenoviral vector and being integrated in the genome of said

complementation line or inserted into an expression vector;

wherein said complementation line, in particular, comprises:

(i) all or part of the E1A region of the genome of an adenovirus; and
(ii) all or part of the E2 region of said genome; and 
(iii) all or part of at least one region of said genome selected from the E1 B
and E4 regions.
The process according to claim 19, wherein said complementation line
comprises, in particular:


(i) all or part of the E1A region of the genome of an adenovirus;
(ii) all or part of the E2 region of said genome; and
(iii) all or part of the E1B and E4 regions of said genome.
The process according to claim 19 or 20, wherein said complementation line
comprises, in particular, all or part of the E1A region and the whole of the E1B

region of the genome of an adenovirus coding for the early proteins.
The process according to one of claims 19 to 21, wherein said
complementation line comprises, in particular, a portion of the genome of an

adenovirus selected from canine, avian and human adenoviruses.
The process according to claim 22, wherein said complementation line
comprises, in particular, a portion of the genome of a type-5 human

adenovirus.
The process according to claim 23, wherein said complementation line
comprises, in particular, the portion of the genome of a type-5 human

adenovirus:

(i) extending from nucleotide 100 to nucleotide 5297;
(ii) extending from nucleotide 100 to nucleotide 4034; or
(iii) extending from nucleotide 505 to nucleotide 4034.
The process according to one of claims 19 to 24, wherein said
complementation line comprises a portion of the E1A region of the genome of

an adenovirus devoid of its natural promoter; said portion being placed under
the control of a suitable promoter. 
The process according to claim 25, wherein said portion of the E1A region is
placed under the control of a promoter inducible by a non-adenoviral

transcription trans-activator protein.
The process according to one of claims 19 to 26, wherein said
complementation line is derived from a pharmaceutically acceptable cell line.
The process according to claim 27, wherein said complementation line is
derived from a cell line selected from the lines Vero, BHK, A549, MRC5, W138

and CHO.
The process according to one of claims 19 to 26, wherein said
complementation line is derived from a cell of the retina of a human embryo.
A pharmaceutical composition comprising as therapeutic or prophylactic agent
an adenoviral vector according to one of claims 1 to 15, an adenovirus particle

according to claim 16 or obtained by carrying out the process according to one
of claims 18 to 29 or a eukaryotic cell according to claim 17, in association

with a pharmaceutically acceptable carrier.
Use of an adenoviral vector according to one of claims 1 to 15, of an
adenovirus particle according to claim 16 or obtained by carrying out a

process according to one of claims 18 to 29 or of a eukaryotic host cell
according to claim 17 for the preparation of a pharmaceutical composition for

transferring DNA molecules into a cell or a eukaryotic organism.
</CLAIMS>
</TEXT>
</DOC>
